Robert W. (Bob) Taylor, (shown above) 

“As a veteran-owned company, we strive to serve those who are actively working to protect our country,” said Eric Albery, President of Alliant Healthcare. “As a result of this contract, our partnership with Olympus and our ability to better serve our government customers becomes stronger. We are now able to provide federal government customers with access to the highest quality of medical research products on the market, through an efficient, net-centric ordering, distribution, and payment system.” 

ECAT was developed to streamline business practices and expand procurement options for the federal government. ECAT is largely used by Department of Defense customers (including Army, Navy, Airforce, etc.), however, in 2018 the VA healthcare system began using ECAT as well.  The program is a complementary acquisition strategy allowing government customers to browse, compare, and order a wide range of products. 

“We are excited to expand our partnership with Alliant Healthcare to ensure that veterans and federal health facilities have access to state-of-the-art Olympus products via the ECAT contract,” said Jeff Bright, National Director of Sales at Olympus Life Sciences. 

“This contract highlights our company’s ability and determination to supply our country’s defenders with products that help save lives and advance medical research initiatives,” said Bob Taylor, Owner and CEO of Alliant Healthcare. “We are excited to further engage with our federal government customers to better serve our veterans around the world.” 

### 

ABOUT ALLIANT ENTERPRISES, LLC
Robert Taylor is the CEO, founder, and sole owner of Alliant Enterprises, LLC, a CVE verified Service-Disabled Veteran-Owned Small Business formed in 2002 and his second medical device start-up. The original operational focus of the company was to provide contract manufacturing services to various customers. The company established clean room operations and provided contract medical packaging services.

In 2004, Taylor positioned Alliant in a new way to differentiate itself in the market place. The emphasis was to combine contract manufacturing and to add sales and distribution to give the company more growth potential and self-reliance. The company initiated several rounds of financing eventually reaching $5.3 million. The company has repaid all of those initial rounds of funding and now relies only on a standard line of credit for its primary business lending.

In 2008, Alliant was approached to assist a company in expanding its business into the federal government. Taylor made the critical decision that Alliant would not add to the prices being paid by the government for Alliant’s services. To this day, Alliant is paid as a distribution channel and is compensated by the Original Equipment Manufacturer (OEM). For the clear majority of Alliant’s sales to the government, the federal government does not pay extra to work with Alliant. If the government has already established fair and reasonable pricing for the products directly from the OEM, then Alliant honors those prices. It is Taylor’s view that his SDVOSB can add value to the government customers. As an example, the company can consolidate the number of suppliers needed to supply the government - this saves the government time and money. Also, government customers can use a single point of contact for all businesses working with Alliant greatly reducing time and confusion.

Alliant Enterprises, LLC, has three sister companies which are owned by Taylor.

Alliant Healthcare Products, is a channel partner to companies selling into the federal market. Through Alliant’s partners, Alliant can provide newly-constructed turn-key operating rooms, mobile imaging centers, endoscopic devices, imaging equipment, and a host of products used in the daily care of patients. The company also provides state-of-the-art medical technologies such as cryo-preserved umbilical tissue to help treat the difficult wounds of veterans. Key partners include Philips Medical, Olympus Medical, Skytron, Amniox, and Bio Tissue and numerous others. A source of pride is the recognition the company received in 2010 from Inc 500 magazine as the 9th fastest growing healthcare company in the US.

Surge Cardiovascular began in 2010 through an acquisition. The company now self-manufactures, designs and sells perfusion cannula products used in open-heart surgery to arrest the heart while surgeons perform coronary bypass or heart valve replacement. Surge is a global device company with sales in 28 countries and the entire US. The most exciting part of this business is the development of its own products with intellectual property. The company launched eight new products in 2016 and 2017 aimed at less invasive cardiac surgery and other products to help surgeons improve surgical outcomes in open heart surgery. The company expects annual growth to expand at even higher rates over the next three plus years.

Medisurge was started in 2016 when the company stood up an 18,000-square foot facility for clean room contract medical device manufacturing under the regulatory oversight of the FDA, ISO, Canada Health, and Japan’s FDA. Medisurge currently manufactures, packages, and sterilizes urological, cardiac, and general surgical devices for four major medical device companies. Medisurge has a unique value proposition due to its advanced and lean manufacturing. Lean manufacturing is the ability to drive down costs and to improve and accelerate customers’ results. The advanced manufacturing proposition is a recognition of the very aggressive cost drivers in healthcare today. Medisurge is building the factory of the future.